All In Biotech

Drug Trial Radar · NCT07859839

Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD

A Randomized, Open-labelled, Three-Arm Trial of Gabapentin Versus Benzonatate Versus Standard of Care for Chronic Cough in Interstitial Lung Disease

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

177

Planned (sponsor's estimate)

Start

Oct 7, 2026

Primary completion

Jun 30, 2027

Study completion Jul 31, 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
Oct 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area. In this study, the investigators aim to compare gabapentin and benzonatate treatment with the standard of care for treating chronic cough in ILD. The investigators hypothesize that both gabapentin and benzonatate will be more effective than standard of care in treating chronic cough in ILD.

Conditions

  • Interstitial Lung Disease

Interventions

  • GabapentinDrug

    Gabapentin at starting dose of 100 mg per dose, thrice daily and up titrated by 100 mg per dose every 3 days till 300 mg per dose, thrice daily or maximum tolerated dose

  • Benzonatate 200 mgDrug

    Benzonatate at starting dose of 100 mg per dose thrice daily and up titrated to 200 mg per dose thrice daily after 3 days

  • Standard of care treatment for ILDOther

    Standard Therapy including immunosuppressive and/or anti-fibrotic agent/s and symptomatic therapy for cough (as needed dextromethorphan lozenges)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cough intensity in Gabapentin groupTime frame: 8 weeks
  2. Cough intensity in benzonatate armTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Postgraduate Institute of Medical Education and Research

    Chandigarh, Chandigarh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.